Internal Medicine | Page 237 of 476 | Links Medicus Content Curation & Alerts in Medicine

More potential evidence against antibody drugs late in course of #COVID19: Regeneron says independent cmte has recommended not enrolling pts on high oxygen into trial "based on a potential safety signal and an unfavorable risk/benefit profile at this time" https://t.co/moHtuhV9cP

— Meg Tirrell (@megtirrell) October 30, 2020

CDC Report: Transmission of SARS-COV-2 infections in households

2 Nov, 2020 | 02:37h | UTC

Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020 – CDC Morbidity and Mortality Weekly Report

Commentaries: A new CDC study suggests roughly 50% of people living with someone who has COVID-19 get it — usually in less than 5 days – Business Insider AND Household spread of Covid-19 is common and quick, a new CDC study finds – CNN

Commentaries on Twitter

New CDC study finds that children pass along Covid to household members just as frequently as adults do. This underscores why it's crucial to contain the virus among all populations. https://t.co/sZHOh1wOG3

— Dr. Tom Frieden (@DrTomFrieden) October 31, 2020

(1/7) Important prospective study of household transmission by CDC, suggesting children and adults are similarly likely to transmit #SARSCoV2. The household secondary attack rate was at least 35%, and 18% of cases were asymptomatic.https://t.co/iEdx2VBPXz pic.twitter.com/mq4LxSoU0J

— Dr Zoë Hyde (@DrZoeHyde) October 31, 2020

Trends in COVID-19 risk-adjusted mortality rates

2 Nov, 2020 | 02:24h | UTC

Trends in COVID-19 Risk-Adjusted Mortality Rates – Journal of Hospital Medicine

Commentary: Study reveals factors that account for reduced death rates from COVID-19 – NYU School of Medicine / News Medical

Commentary on Twitter

Trends in COVID-19 Risk-Adjusted Mortality Rates | Journal of Hospital Medicine: “Data from one health system suggest that mortality from COVID-19 is decreasing even after accounting for patient characteristics.” https://t.co/AtQ6lPnzhQ

— Dr. Ron Daniels BEM (@SepsisUK) October 25, 2020

Can covid-19 help us deal with the pandemic of defensive medicine?

2 Nov, 2020 | 02:28h | UTC

Can covid-19 help us deal with the pandemic of defensive medicine? – The BMJ Opinion

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

2 Nov, 2020 | 02:18h | UTC

Efficacy and Safety of Colchicine in Patients With Chronic Stable Coronary Disease – American College of Cardiology

Report: COVID-19 infection fatality ratio estimates from seroprevalence

30 Oct, 2020 | 01:16h | UTC

Report 34 – COVID-19 Infection Fatality Ratio Estimates from Seroprevalence – Imperial College London

Full report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence

Commentary on Twitter

UPDATE #COVID19 Infection Fatality Ratio (IFR):

➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age

?Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf

— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020

Case study: Urinary magnesium in the evaluation of hypomagnesemia

2 Nov, 2020 | 02:19h | UTC

Urinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

30 Oct, 2020 | 01:14h | UTC

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science

Commentaries on Twitter

Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG

— Jon Cohen (@sciencecohen) October 28, 2020

Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5

— Eric Topol (@EricTopol) October 28, 2020

Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations

30 Oct, 2020 | 01:04h | UTC

Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases – The BMJ

Commentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly

Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

29 Oct, 2020 | 09:16h | UTC

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 – New England Journal of Medicine

Audio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine

Commentaries on Twitter

BLAZE-1? – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial

Only 1 of the 3 mAb dosages (middle one ?‍♂️) ⬇️ VL by d11

mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)

? Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA

— Ilan Schwartz MD PhD (@GermHunterMD) October 28, 2020

Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD

— Eric Topol (@EricTopol) October 28, 2020